Etanercept and psoriasis, from clinical studies to real life.
OBJECTIVE
To determine whether etanercept therapy enables long-term psoriasis patients to discontinue systemic psoriatic therapy.


METHODS
Charts from psoriatic patients on etanercept therapy seen at the Department of Dermatology and Dermatolgic Surgery, University of Miami, Miami, FL, USA, between June 2002 and October 2003, were evaluated retrospectively. The duration of disease, adverse events to "standard" systemic psoriatic therapy, and current therapy were reviewed. IRB: 03/582C.


RESULTS
A large proportion of patients (73.5%) were able to decrease or discontinue their traditional systemic agent while on etanercept.


CONCLUSIONS
Etanercept is a safe and effective therapy in chronic moderate to severe psoriasis. In patients who are receiving systemic therapy for their disease and alternative therapy is warranted, etanercept can be added with the aim to discontinue the other systemic agents.
Jacob
Sharon E
SE
Department of Dermatology and Cutaneous Surgery, University of Miami/Jackson Memorial Medical Center, Fl 33101, USA. sjacob@med.miami.edu
Sergay
Amanda
A
Kerdel
Francisco A
FA
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept